Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding. The CE Mark approval comes after studies Xience 28 and Xience 90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most…
Watch again our Webinar on Short Dual Therapy in Patients with High Bleeding Risk
Watch again our Webinar on “Short Dual Therapy in Patients with High Bleeding Risk” on our Youtube account. The event was held on 12/08/2020 and had the participation of more than 200 people and the support of ABBOTT. What things will I learn if I watch this video? 04:02 | Innovation: Short Dual Therapy in…